Department of Nursing, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1095 Jiefang Avenue, Qiaokou District, Wuhan, 430030, China.
School of Nursing, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Support Care Cancer. 2023 Apr 26;31(5):303. doi: 10.1007/s00520-023-07763-x.
The experiences of patients with diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor (CAR) T-cell therapy have received little attention. This study aimed to explore the treatment experiences of patients with relapsed or refractory (R/R) B-cell lymphoma during CAR T-cell therapy in China.
This descriptive qualitative study was conducted using face-to-face semi-structured interviews with 21 DLBCL patients 0-2 years after CAR-T infusion. Two researchers independently coded the interviews in MAXQDA 2022, and the original data were analyzed by conventional content analysis.
Four themes emerged from the transcripts: (1) physiological distress, (2) functional impacts, (3) psychological experience, and (4) support requirement. Participants expressed 29 short-term or long-term symptoms related to their disease and treatment, influencing their daily life and function in a social setting. The participants expressed different negative emotions, polarized expectations about efficacy, and over-reliance on authoritative medical care. Their major concerns and hopes were achieving life goals, being treated with respect, obtaining more information about CAR T-cell therapy, and receiving government financial sponsorship.
The patients experienced short-term and long-term symptoms of physical distress. Patients who have experienced failure in CAR T-cell therapy also experience strong negative emotions, such as dependency and guilt. They also require authentic spiritual and financial information that is authentic. Our study may guide the development of standardized and comprehensive nursing care for R/R DLBCL patients undergoing CAR T-cell therapy in China.
嵌合抗原受体（CAR）T 细胞治疗弥漫性大 B 细胞淋巴瘤（DLBCL）患者的治疗体验尚未得到充分关注。本研究旨在探讨中国接受 CAR T 细胞治疗的复发/难治性（R/R）B 细胞淋巴瘤患者的治疗体验。
本描述性定性研究采用面对面半结构式访谈，对 CAR-T 输注后 0-2 年的 21 例 DLBCL 患者进行访谈。两名研究人员在 MAXQDA 2022 中独立对访谈进行编码，使用常规内容分析法对原始数据进行分析。
转录本中出现了 4 个主题：（1）生理困扰，（2）功能影响，（3）心理体验，（4）支持需求。参与者表达了 29 种与疾病和治疗相关的短期或长期症状，这些症状影响了他们在社会环境中的日常生活和功能。参与者表达了不同的负面情绪、对疗效的两极化期望以及对权威医疗的过度依赖。他们主要关注的是实现生活目标、得到尊重、获得更多关于 CAR T 细胞治疗的信息以及获得政府财政资助。
患者经历了短期和长期的身体不适症状。经历过 CAR T 细胞治疗失败的患者也会经历强烈的负面情绪，如依赖和内疚。他们还需要真实的精神和财务信息。我们的研究可以为中国接受 CAR T 细胞治疗的 R/R DLBCL 患者制定标准化和全面的护理提供指导。
